BAC vs MIRM Stock Comparison

BAC currently leads MIRM in this stock comparison, with AIQ scores of 58 vs 53. The clearest difference is risk resilience, while MIRM has the stronger momentum profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 5 points
BAC
Financial Services
vs
MIRM
Healthcare
BAC
Bank of America Corporation
Leads
Price
$51.02
Day move
+1.01%
AIQ Score
58/100
Best edge
Risk Resilience
Sector
Financial Services
MIRM
Mirum Pharmaceuticals, Inc.
Price
$93.99
Day move
+0.71%
AIQ Score
53/100
Best edge
Momentum
Sector
Healthcare

What is the main difference between BAC and MIRM?

BAC leads the current stock comparison as Bank of America Corporation, with the clearest separation coming from risk resilience and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Bank of America Corporation vs Mirum Pharmaceuticals, Inc.

Data as of Nov 15, 2026· market close· Cross-sector · Financial Services vs Healthcare· Coverage 65/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 3/10

BAC leads

BAC leads by 5 AIQ points, primarily on Risk Resilience and Quality, but the lead has narrowed from 15 points over 30 sessions. Wall Street currently favors MIRM on target upside.

Fragile: 3 of 6 evidence groups support BAC, its lead is narrowing, and its current signal state is conflicted.

Evidence agreement: 3 of 6Comparison trend: Weakening
BAC

Bank of America Corporation

Leads
AIQ Score
58/100
AIQ Edge Score
6/10
MIRM

Mirum Pharmaceuticals, Inc.

AIQ Score
53/100
AIQ Edge Score
5/10

The Algovestiq AIQ Score currently favors BAC over MIRM, 58 versus 53 as of Nov 15, 2026. BAC's advantage is driven primarily by stronger risk resilience and quality, while MIRM holds the stronger momentum profile. BAC also shows the weaker technical structure relative to its 50-day moving average, though analyst target upside currently favors MIRM. 3 of 6 covered evidence groups favor BAC today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 5 points. BAC lead: Weakening — the AIQ differential moved from 15 to 5 points over 30 sessions.

Compare Bank of America Corporation and Mirum Pharmaceuticals, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Total return with distributions reinvested, from daily closes.

BAC
+24.0%
MIRM
+508.0%

Total return comparison

Growth of $10,000, distributions reinvested

BAC $12,399 · MIRM $60,796

Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.

Compare BAC and MIRM against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

BAC advantage
0
MIRM advantage
  • Risk Resilience83 vs 51
    BAC +32
  • Momentum37 vs 54
    MIRM +17
  • Quality64 vs 52
    BAC +12
  • Value68 vs 57
    BAC +11

3 of 6 evidence groups favor BAC. BAC’s edge is concentrated in risk resilience and quality; MIRM keeps a meaningful momentum edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

BAC0 AIQ

No factor moved materially.

New signals

  • OBV Bullish Divergence — bullish, volume, medium horizon (-0.4%)
MIRM+1 AIQ

Largest factor move: Momentum +2

No signal started or stopped since the prior session; its 4 active signals are unchanged.

BAC's lead narrowed by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — BAC and MIRM both carry a full feed there.

The central trade-off

BAC (Bank of America Corporation): the stronger current systematic profile, led by risk resilience and quality.

MIRM (Mirum Pharmaceuticals, Inc.): the counter-case, on momentum, fundamentals, technicals — but at materially higher volatility, 50.6% against 24.8%.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

BAC

BAC on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

MIRM

MIRM on combined revenue and EPS growth.

Value

BAC

BAC on the peer-relative Value factor, by 11 points.

Momentum

MIRM

MIRM on the Momentum factor, by 17 points.

Lower downside

BAC

BAC on Risk Resilience, by 32 points.

Analyst upside

MIRM

MIRM on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors BAC, analyst targets favor MIRM. That disagreement is the most useful thing on this page.

MeasureBACMIRMNote
Implied upside to target+24.1%+66.9%MIRM has more room
Target dispersion+25.3%+45.9%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering2514Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 6 covered evidence groups favor BAC. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreBAC58 vs 53
FundamentalsMIRMon balancerevenue growth -3.3% vs 5.4%; EPS growth -23.8% vs 41.5%; TTM ROE 2.3% vs 75.2%; gross margin 60.4% vs 81.7%; operating margin 22.4% vs -25.3% — MIRM takes 4 of 5 decided legs, not all of them
ValuationBACValue 68 vs 57
TechnicalsMIRMPrice vs 50-day -5.6% vs 5.9%; vs 200-day -7% vs -4.5%
Risk ResilienceBACRisk Resilience 83 vs 51
Analyst expectationsMIRMTarget upside 24.1% vs 66.9%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BAC and MIRM and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is narrow at 5 points. (argues the conclusion is provisional)
  • Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BAC.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

BAC lead: Weakening — the AIQ differential moved from 15 to 5 points over 30 sessions.

May 27BAC leads above the line · MIRM leads belowNov 13
Today
BAC +5
58 vs 53
7 sessions ago
BAC +8
58 vs 50
30 sessions ago
BAC +15
62 vs 47
90 sessions ago
BAC +18
71 vs 53

The lead changed hands 3 times in this window, most recently on Jul 17 when BAC moved ahead of MIRM.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

BACConflicted

2 bullish / 2 bearish / 1 neutral, conflicted

Only BAC

  • Bollinger Band Squeeze — neutral, volatility, short horizon (4.5%)
  • Downtrend Structure Active — bearish, trend, long horizon
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
  • OBV Bullish Divergence — bullish, volume, medium horizon (-0.4%)
MIRMConflicted

1 bullish / 2 bearish / 1 neutral, conflicted

Only MIRM

  • ATR Expansion - Breakout Mode — neutral, volatility, short horizon (4.21%)
  • Low Volume Rally Warning — bearish, volume, short horizon (0.54x)
  • TRIX Bullish Signal — bullish, momentum, short horizon

Both carry 1 more signal that do not separate them: Death Cross Active.

BAC leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

BACNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.01%, AIQ 0 points).

MIRMConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +0.71%, AIQ +1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1MIRM closes the Risk Resilience gap — currently 32 points behind, the largest single contributor to BAC's edge.
  2. 2MIRM's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3BAC's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once.
  4. 4The narrowing continues — the lead has already given back 10 points over 30 sessions, and a further 5-point move would eliminate BAC's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

MIRM leads on balance
MetricBACMIRM
Revenue growth (YoY)-3.3%5.4%
EPS growth (YoY)-23.8%41.5%
Gross margin60.4%81.7%
Operating margin22.4%-25.3%
Return on equity (TTM)2.3%75.2%
Debt to equity1.28-13.72

Performance

MIRM leads 4 of 6 windows
MetricBACMIRM
1 week (5 sessions)3.2%0.3%
1 month (20 sessions)-0.4%17.3%
3 months (63 sessions)-20.1%-5.8%
6 months (126 sessions)2.5%-8%
Year to date-7.2%19%
1 year (252 sessions)-5.7%32.8%

Technicals

MIRM has the stronger structure
MetricBACMIRM
RSI (14)45.959.9
ADX (14)27.226.1
Price vs 50-day-5.6%5.9%
Price vs 200-day-7%-4.5%
Volatility (1M, annualized)24.8%50.6%

Risk

BAC is the more resilient
MetricBACMIRM
Beta0.791.07
Sharpe ratio-0.220.79
Sortino ratio-0.291.12
Max drawdown-23.7%-38.4%
Current drawdown-21.3%-26.9%
Annualized volatility22.4%48.6%
Value at risk (95%)-2.6%-4.9%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, BAC or MIRM?

On the Algovestiq AIQ Score, BAC is the stronger of the two as of Nov 15, 2026, scoring 58 against MIRM's 53. The edge comes from risk resilience and quality. MIRM is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is BAC or MIRM the better buy right now?

BAC carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 5 points. Treat the lead as provisional.

Why does the AIQ Score favor BAC over MIRM?

The composite weights Quality, Value, Momentum and Risk Resilience. BAC leads Risk Resilience by 32 points; MIRM leads Momentum by 17 points; BAC leads Quality by 12 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, BAC or MIRM?

Analyst price targets imply +24.1% upside for BAC and +66.9% for MIRM, so the Street currently favors MIRM. That points the opposite way to the AIQ Score, which favors BAC. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, BAC or MIRM?

BAC is the better-valued of the two on the peer-relative Value factor. BAC on the peer-relative Value factor, by 11 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, BAC or MIRM?

MIRM on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, BAC or MIRM?

MIRM on the Momentum factor, by 17 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, BAC or MIRM?

BAC is the more resilient of the two, so the other name carries the higher downside risk. BAC on Risk Resilience, by 32 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is BAC more profitable than MIRM?

The profitability evidence is mixed: gross margin 60.4% vs 81.7%; operating margin 22.4% vs -25.3%; ttm roe 2.3% vs 75.2%. BAC leads on one measure and MIRM on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is BAC's lead over MIRM getting stronger or weaker?

BAC lead: Weakening — the AIQ differential moved from 15 to 5 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 3 times in that window, most recently on 2026-07-17, when BAC moved ahead of MIRM.

What would change the BAC vs MIRM verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: MIRM closes the Risk Resilience gap — currently 32 points behind, the largest single contributor to BAC's edge; MIRM's Death Cross Active resolves — a bearish trend rule currently active against it; BAC's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once; the narrowing continues — the lead has already given back 10 points over 30 sessions, and a further 5-point move would eliminate BAC's advantage entirely.

What do the current signals say about BAC and MIRM?

BAC: 2 bullish / 2 bearish / 1 neutral, conflicted. MIRM: 1 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BAC is Death Cross Active (bearish, long horizon). On MIRM it is Death Cross Active (bearish, long horizon).

Compare BAC and MIRM with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.